Markets:

Overview

News

Currencies

International

Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

4.749 -0.261 (-5.22%)

Streaming Delayed Price Updated: 11:23 AM EDT, Jul 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

March 11, 2025

From Agenus Inc.

Via Business Wire

Earnings Scheduled For March 11, 2025 ↗

March 11, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Insights Ahead: Agenus's Quarterly Earnings ↗

November 11, 2024

Via Benzinga

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

February 26, 2025

From Agenus Inc.

Via Business Wire

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

February 25, 2025

From Agenus Inc.

Via Business Wire

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

February 25, 2025

From Agenus Inc.

Via Business Wire

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

February 24, 2025

From Agenus Inc.

Via Business Wire

CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

February 23, 2025

From Agenus Inc.

Via Business Wire

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

January 29, 2025

From Agenus Inc.

Via Business Wire

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

January 22, 2025

From Agenus Inc.

Via Business Wire

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

December 18, 2024

From Agenus Inc.

Via Business Wire

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

December 05, 2024

From Agenus Inc.

Via Business Wire

Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development ↗

November 27, 2024

Agenus secures a $22M mortgage and announces a strategic realignment to focus on botensilimab/balstilimab in MSS colorectal cancer.

Via Benzinga

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

November 27, 2024

From Agenus Inc.

Via Business Wire

Agenus (AGEN) Q3 2024 Earnings Call Transcript ↗

November 12, 2024

AGEN earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

November 12, 2024

From Agenus Inc.

Via Business Wire

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

November 07, 2024

From Agenus Inc.

Via Business Wire

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

November 05, 2024

From Agenus Inc.

Via Business Wire

DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Agenus to Contact Us to Have Their Losses Evaluated Today

November 02, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

October 30, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Allarity, ZoomInfo, and Agenus and Encourages Investors to Contact the Firm

October 29, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline

October 28, 2024

From Bernstein Liebhard LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Agenus, and New Fortress and Encourages Investors to Contact the Firm

October 22, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline

October 21, 2024

From Bernstein Liebhard LLP

Via GlobeNewswire

RLF Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN

October 19, 2024

From The Rosen Law Firm PA

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Agenus, ZoomInfo, and Super Micro and Encourages Investors to Contact the Firm

October 16, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

October 16, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN

October 15, 2024

From The Rosen Law Firm PA

Via GlobeNewswire

AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline

October 14, 2024

From Bernstein Liebhard LLP

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.